Induced pluripotent stem cell-derived vascular networks to screen nano-bio interactions by Estronca, Luís et al.
This journal is©The Royal Society of Chemistry 2021 Nanoscale Horiz.
Cite this:DOI: 10.1039/d0nh00550a
Induced pluripotent stem cell-derived vascular
networks to screen nano–bio interactions†
Luı́s Estronca,a Vitor Francisco, b Patrı́cia Pitrez,b Inês Honório,b Lara Carvalho,c
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The vascular bioactivity/safety of nanomaterials is typically evaluated
by animal testing, which is of low throughput and does not account
for biological differences between animals and humans such as
ageing, metabolism and disease profiles. The development of perso-
nalized human in vitro platforms to evaluate the interaction of
nanomaterials with the vascular system would be important for both
therapeutic and regenerative medicine. A library of 30 nanoparticle
(NP) formulations, in use in imaging, antimicrobial and pharmaceu-
tical applications, was evaluated in a reporter zebrafish model of
vasculogenesis and then tested in personalized humanized models
composed of human-induced pluripotent stem cell (hiPSC)-derived
endothelial cells (ECs) with ‘‘young’’ and ‘‘aged’’ phenotypes in 3
vascular network formats: 2D (in polystyrene dish), 3D (in Matrigel)
and in a blood vessel on a chip. As a proof of concept, vascular
toxicity was used as the main readout. The results show that the
toxicity profile of NPs to hiPSC-ECs was dependent on the ‘‘age’’ of
the endothelial cells and vascular network format. hiPSC-ECs were
less susceptible to the cytotoxicity effect of NPs when cultured in
flow than in static conditions, the protective effect being mediated, at
least in part, by glycocalyx. Overall, the results presented here high-
light the relevance of in vitro hiPSC-derived vascular systems to
screen vascular nanomaterial interactions.
1. Introduction
Nanomaterials and nanomaterial-based technologies enable
the development of new materials and applications across
disciplines, including mechanical and electrical engineering,
agriculture, energy generation and medicine.1–3 The inter-
actions of these nanomaterials with the human body are only
partially known.4–6 The development of new cell-based plat-
forms for the rapid profiling of nanomaterials in terms of
bioactivity, toxicity, and biodegradation, among other aspects,
is in great need.7,8 The majority of the nanomaterials that enter
the human body, independent of the route of entry, will
certainly circulate and be transported in the vascular system
through the blood vessels and therefore it is critical to study
their impact in individuals with differences in their vascular
biology because of their genetic background or pathologies.
The effects of nanomaterials in the disruption of the integrity of
endothelial cell–cell communication9 and in the induction of
endothelial10 and smooth muscle11 cell toxicity have been identified.
Standard protocols for assessing the effect of nanomaterials on
the vascular system involve testing in animals.5,10 Unfortunately,
these tests are of low-throughput, and expensive, yield limited
a Faculty of Medicine, University of Coimbra, 3000-548, Coimbra, Portugal.
E-mail: lino@uc-biotech.pt
b Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra,
Portugal
c Instituto de Medicina Molecular e Instituto de Histologia e Biologia do
Desenvolvimento, Faculdade de Medicina da Universidade de Lisboa, 1649-028,
Lisboa, Portugal
d CECS, I-STEM, AFM, Institute for Stem Cell Therapy and Exploration of
Monogenic diseases, Evry cedex, France
e Institute of Inorganic Chemistry, RWTH Aachen University, Germany
† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0nh00550a
Received 17th September 2020,




The exposure of humans to environments with increased levels of nano-
particles in the air as well as to pharmaceutical nanoformulations for
regenerative and therapeutic medicine requires a better knowledge of their
bioactivity/safety. In the past, these tests were performed in low throughput
in vivo tests (e.g. mice) that did not account for differences with the human
system and in non-personalized human cells, i.e., in cells that did not have
patient-specific information and ageing signatures. In this study, we have
developed personalized vascular networks with variable complexity (2D, 3D,
and a blood vessel on a chip) formed by human induced pluripotent stem
cell-derived endothelial cells with a ‘‘young’’ or ‘‘aged’’ phenotype, to screen
vascular–nanomaterial interactions. We have used a library of 30 nanoma-
terials with different physico-chemical properties and relevance for clinical
molecular imaging, protective formulations, antimicrobial coatings,
catalysis and pharmaceutical applications. The complexity of the vascular
network, and particularly its ability to express glycocalyx, as well as the age
of the cells influenced largely their sensitivity to the nanomaterials. The
platform presented in this study is very promising for high-throughput
screening of nano–bio interactions and for the identification of nanomater-
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mechanistic information, do not address the current policies of
regulatory agencies to use alternatives to animal testing, and do
not account for differences between species. Moreover, with the
advent of personalized medicine, new cell technologies are required
to provide patient-specific information about nanomaterial
bioactivity/safety. In this respect, human-induced pluripotent
stem cells (hiPSCs) represent a potential source of endothelial
cells (ECs) and smooth muscle cells (SMCs).12–14 These humanized
systems are, in some aspects, superior to animal models because
they recapitulate human ageing, metabolism and disease profiles.
Unfortunately, hiPSC-derived ECs and SMCs have not been used to
study the bioactivity/safety of nanomaterials among different
individuals. These cells may be cultured under flow shear condi-
tions in microfluidic systems to better mimic the in vivo conditions.
In this work, the impact of nanomaterials in iPSC-derived
vascular networks was evaluated in 2D, 3D and blood vessel on
a chip in vitro models. While the first two models run in static
conditions, the blood vessel on a chip model runs in flow
conditions, similar to in vivo conditions, which allows the
formation of a functional glycocalyx layer on top of endothelial
cells. Thirty nanomaterials that are normally used for different
applications such as clinical molecular imaging, protective
formulations, antimicrobial coatings, pharmaceutical formulations
and catalysts have been selected (Fig. 1). The nanomaterials with a
metallic or polymeric composition and sizes ranging between
1.4 and 400 nm were initially tested in the zebrafish embryo
vasculogenesis/angiogenesis to investigate their in vivo effect.
Subsequently, the nanomaterials were tested in the in vitro
human iPSC-derived vascular networks from two individuals
in the same timeframe as the zebrafish tests (i.e. 24 h) to
evaluate their acute toxicity. One of the iPSC lines was derived
from fetal cells (cord blood of a healthy newborn), while the
other was generated from fibroblasts of a 14 year-old female
patient with Hutchinson–Gilford progeria syndrome (HGPS).15
HGPS is a rare and fatal disease caused by a single point
mutation of the LMNA gene leading to the accumulation of an
abnormally truncated lamin A protein called progerin, which
in turn leads to accelerated ageing.16 The accumulation of
progerin is also observed during physiological ageing, although
at much lower levels.17 The motivation here was to investigate
differences in the interaction of nanomaterials with vascular
cells with a ‘‘young’’ and ‘‘aged’’ phenotype. As a proof of concept,
we have selected vascular toxicity as the main readout because it is
relatively easy to quantify; however, cellular NP internalization was
also quantified in some experiments. We have used monoculture of
both iPSC-derived ECs either in polystyrene culture dishes (2D) or
in Matrigel (3D) to screen, in static conditions. Some of the toxic
formulations were further tested in a blood vessel on a chip
formed by a co-culture of iPSC-ECs and iPSC-SMCs.
2. Results
Characterization of nanomaterials
We have selected 30 nanomaterials, both organic and inorganic,
with different sizes and zeta potentials to evaluate in our
vascular screening platform (Table 1). We focused on nano-
materials used for: (i) molecular imaging (NP4), (ii) sunscreen
(NP15 and NP16), (iii) antimicrobial applications (NP29, NP918
or NP1219), (iv) pharmaceutical applications (NP20 and NP21,20
NP24,21 and light-triggerable formulations recently synthesized
by us such as NP30, NP23, NP26, NP27, NP18 (all described in
reference ref. 22), NP22,23 NP14,23 and NP2524) and (v) reaction
catalysis or biomedical applications (NP1, NP2, NP3, NP5, NP6,
NP7, NP8, or silica-based NPs such as NP13 and NP28). Many of
these NPs may get inside of the human body and interact with
blood vessels in the circulation. Dynamic light scattering (DLS)
analyses showed that the average sizes of the inorganic nano-
materials suspended in PBS varied between 1 (NP1) and 360 nm
(NP29), while those for organic nanomaterials varied between 32
(NP10) and 427 nm (NP30) (Fig. 2A.1 and A.2). Most of the
nanomaterials maintained their size after 24 h in suspension
with a few exceptions (NP8 and NP16 slightly increased their
diameters while NP28 decreased significantly their diameters,
likely due to a poor initial dispersion of the NPs as shown by
Fig. 1 NP library and in vivo/in vitro models to screen their toxicity.
(A) Properties of the NPs. The NPs can be categorized based on their size
as: ultrasmall (3 NPs) or small (27 NPs); based on their composition as:
inorganic (15 NPs) or organic (15 NPs); and by the type of the coating:
peptides (3), polymers (2), functional groups (4) or anti-oxidants (2).
(B) In vivo and in vitro models to screen NP toxicity. In vivo model:
30 NPs were tested at 1 mg mL1 in 4 hpf zebrafish embryos (manually
dechorionated) for 24 h. The readout was vasculogenesis. 2D model (in
culture plates, static conditions): 30 NPs were incubated at 4 different
concentrations (6, 12.5, 25 and 50 mg mL1) for 24 h with N-iPSC ECs or
HGPS-iPSC ECs. The readouts were: (i) cell survival and (ii) nanomaterial
internalization. 3D model (in Matrigel, static conditions): 30 NPs were
incubated at 2 concentrations (12.5 and 25 mg mL1) together with iPSC
ECs in culture plates with Matrigel for 24 h. The readouts were: (i) length of
microvessels formed, (ii) cell survival and (iii) gene expression. Blood vessel
on a chip (microfluidic system; flow conditions): 10 NPs were tested at
50 mg mL1 in arterial flow conditions in a co-culture of N-iPSC SMCs and




































































































This journal is©The Royal Society of Chemistry 2021 Nanoscale Horiz.
TEM analyses, see below). The hydrodynamic diameter of
the nanomaterials ranged between 1.1 and 427 nm. Trans-
mission electron microscopy (TEM) analyses were performed to
confirm the sizes and shapes of some of the nanomaterials
(Fig. S1, ESI†).
To study the effect of salts and proteins on NP size and
stability, the hydrodynamic diameters of NPs (suspended at a
concentration of 50 mg mL1) was evaluated by DLS in a cell
culture medium with serum (2% fetal bovine serum (FBS);
concentration of serum used to culture ECs) for 24 h (duration
of most in vitro experiments) (Fig. 2A.3 and A.4). In the cell culture
medium, with some exceptions (NP12, NP14, NP18, NP29 and
NP30 increased their diameters, while NP16 and NP17 slightly
decreased their diameters), the NPs maintained their diameters
for at least 24 h. The hydrodynamic diameters of the NPs
ranged between 1.1 and 357 nm. All the NPs showed a negative
zeta potential in cell culture medium, which indicates that
proteins and salts have adsorbed on their surfaces (Fig. 2B).
The most negatively charged NP was NP29. Overall, we have
selected a library of NPs that is relevant for biomedical and
environmental applications. These NPs maintained a reasonable
level of stability in the cell culture medium for at least 24 h.
Nanomaterial screening in zebrafish
We evaluated the effect of the nanomaterials in vasculogenesis
and angiogenesis using the zebrafish transgenic Tg(fli1a:
EGFP)y1 line.26 In this transgenic line, the promoter of the
endothelial marker fli1 drives the expression of EGFP in blood
vessels, thus allowing the in vivo analysis of the vasculature. In
zebrafish embryos, the circulation begins after 24 h-post-
fertilization (hpf) in a single circulatory loop.27 Vasculogenesis of
the dorsal aorta, cardinal vein and a primitive cranial vasculature
occurs at this stage.28 After the formation of this primitive
vasculature, the formation of new blood vessels occurs via
angiogenesis, the intersegmental vessels (ISVs) of the trunk
being among the first angiogenic vessels to be formed.29 The
ISVs sprout from the dorsal aorta along the somite boundaries,
which ultimately interconnect between each other to form the
dorsal longitudinal anastomotic vessel (DLAV) (Fig. S2A, ESI†).
Having this in mind, we evaluated the effect of nanomaterials in
the vascular development of ISVs during the first 24–28 hpf.
Fertilized embryos were selected and manually dechorionated to
avoid any interference of the chorion in the internalization of
the NPs. Indeed, previous studies have demonstrated that the
presence of the chorion may affect the toxicity of some NPs.30
For example, Ag NPs caused higher mortality and malforma-
tions in embryos without chorion as compared with embryos
with chorion at the same concentrations.30 In our study, the
dechorionation caused higher sensitivity of the embryos to their
Table 1 Summary of the NP sources and properties
NP number Core Ligand Size (nm) Zeta (mV) Source/ref. NP number Core Ligand Size (nm) Zeta (mV) Source/ref.
NP1 Au MS 1.4 — 25 NP16 TiO2 — 10–30 — ssnano.com
NP2 Au GSH 1.5 — 25 NP17 PS COOH 100 — micromod.de
NP3 Au HA 5  1a 25  2a N.A. NP18 C11 — 65  5 14  1 22
NP4 SPION DEX 40 31 biopal.com NP19 PS NH2 100 — micromod.de
NP5 Au MS 13.9 — NP20 PLGA — 170  7 9  3 20
NP6 Au GSH 12 — NP21 PLGA–PS — 218  9 7  2 20
NP7 Au MS 15  1.5 — 25 NP22 P1C5 — 350  35 21  2 23
NP8 Au HA 20  3a 26  3a N.A. NP23 A9 — 265  23 21  2 22
NP9 Au LL37 21  8 15  2 18 NP24 PEI:DS — 91  6 15  3 21
NP10 PM COOH 25 — micromod.de NP25 PEI–DMNC:DS — 108  10 27  2 24
NP11 PM NH2 25 — micromod.de NP26 E1 — 330  24 7  1 22
NP12 Au CM 14  1 28  2 19 NP27 E2 — 260  18 2  2 22
NP13 SiO2 — 7–14 — plasmachem.com NP28 SiO2 — 10–20 — ssnano.com
NP14 P1C7 — 74  10 19  1 23 NP29 Ag — o6000 — sciessent.com
NP15 ZnO — 10–30 — ssnano.com NP30 A1 — 420  14 1  1 22
a Determined in water by DLS (n = 3). Ligands: MS – sodium 3-(diphenylphosphino)benzene sulfonate; GSH – glutathione; HA – hyaluronic acid;
DEX – dextran; LL37 – antimicrobial peptide; CM – cecropin melittin.
Fig. 2 Physicochemical characterization of the NP library. (A) NP sizes
and counts measured by dynamic light scattering at 0 and 24 h in PBS
(A.1 and A.2) and EGM-2 medium (A.3 and A.4). (B) Zeta potentials of NP
library at 0 h (in molecular biology grade water) and 24 h (in EGM-2
medium). After 24 h in EGM-2, the NPs were centrifuged and resuspended
in H2O for zeta potential measurements. In A and B, results are expressed
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environment, so we used NPs at a concentration of 1 mg mL1.
The number of ISVs, the average length of the first 10 ISVs and
the total lengths of the ISVs were evaluated (Fig. 3 and Fig. S2B,
ESI†). Our results showed that some NPs had a negative impact
on angiogenesis by decreasing the length of ISVs (NP1, NP3,
NP4, NP7, NP8, NP14, NP17, NP18, NP21, NP24, NP25 and
NP26) whereas one nanomaterial (NP9) had a positive impact
on angiogenesis by increasing the length and number of ISVs
(although not statistically significant relative to control). The
pro-angiogenic activity of LL37–Au NPs is aligned with our
previous results showing that these NPs promoted neovascular-
ization in a wound healing animal model.18
Development of a vascular screening platform based on
iPSC-derived vascular cells: derivation of endothelial
cells from hiPSCs
iPSC lines were differentiated into ECs according to a protocol
previously reported by us in ref. 13 (Fig. 4A). Undifferentiated
cells were cultured in chemically defined medium supplemented
with BMP4 and FGF-basic for 5 days to generate mesoderm
progenitor cells followed by their differentiation into endothelial
progenitor cells (PECAM1+ cells) in a medium containing VEGF
and Tb4 for an additional 5 days. PECAM1+ cells were then
selected using magnetism-activated cell sorting and cultured for
up to 7 passages in an endothelial medium supplemented with
VEGF165 and TGF-b inhibitor (SB431542). Gene expression analysis
in cells differentiated for 7 passages (between 24 and 28 days after
cell seeding) indicated that both N-iPSC ECs (from non-disease
cord blood cells) and HGPS-iPSC ECs expressed EC markers such
as PECAM1, CDH5, KDR and vWF as human umbilical artery ECs
(HUAECs), although with some fluctuations in the expression of
these markers (Fig. 4B). In general, the mRNA levels of the EC
markers were higher in HGPS-iPSC ECs than in N-iPSC ECs.
Fig. 3 Impact of nanomaterials on the embryonic vascular development
of zebrafish embryos. (A) Representative fluorescence microscopy images
(all embryos and magnification of the first 10 ISVs) of zebrafish embryos
with B28 hpf in control conditions (vehicle) and after 24 h treatment with
NP9 and NP14. Scale bar is 200 mm. (B.1) Impact of 24 h incubation of
nanomaterials on the average length of the first 10 ISVs of zebrafish
embryos with B28 hpf. (B.2) Impact of 24 h incubation of nanomaterials
on the total ISV length of zebrafish embryos with B28 hpf. (B.3). Impact of
24 h incubation of nanomaterials on the total number of ISVs of zebrafish
embryos with B28 hpf. In B.1, B.2 and B.3, results are mean  SEM
(n = 6–24) and statistical analyses were performed by an unpaired t-test.
*, **, and **** denote statistical significance (P o 0.05; P o 0.01;
P o 0.0001) relative to control.
Fig. 4 Characterization of iPSC-ECs. (A) Protocol for the differentiation of
N-iPSCs and HGPS-iPSCs into EC cells. Undifferentiated iPSCs were
transferred to Petri dishes coated with fibronectin and were cultured in a
differentiation medium for a period of 10 days (see Methods section for
more details), after which the PECAM1+ cells were selected by magnetism-
activated cell sorting and cultured with full culture medium supplemented
with VEGF165 and SB431542 for 7 passages (B25 days) with the medium
changed every 2–3 days. (B) qRT-PCR analyses for the expression of
endothelial and progeria genes. Expression of EC (PECAM1, CDH5, KDR
and vWF) and progeria (progerin, which is encoded by LMNA G608G gene)
markers in HGPS-iPSC and N-iPSCs at passage 7. Human umbilical aortic
endothelial cells (HUAECs) were used as controls. Results are mean  SEM
(n = 3). **, and **** denote statistical significance (P o 0.01, and
P o 0.0001) normalized by the housekeeping gene (GAPDH). Statistical
analyses were performed by an unpaired t-test. (C) Immunofluorescence
analysis performed on HGPS-iPSC ECs and N-iPSC ECs at passage 7 for
ECs (PECAM1, VE-cadherin, and ZO-1), progeria (progerin) and lamin A/C
(inset) markers. Cell nuclei were labelled with DAPI (blue). Scale bar is
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N-iPSC-derived or HGPS-iPSC-derived PECAM1+ cells cultured
for 7 passages expressed high levels of EC markers such
as PECAM1 [by immunocytochemistry (Fig. 4C) and flow cyto-
metry (Fig. S3A, ESI†)], VE-cadherin and ZO-1 at cell–cell
contacts (Fig. 4C) as well as endoglin (CD105). In contrast to
N-iPSC ECs, HGPS-iPSC ECs expressed progerin, the truncated
form of lamin A. Indeed, 61  18% (n = 3) of HGPS-iPSC ECs had
accumulation of progerin, as quantified by immunofluorescence.
The presence of nuclear blebs (characteristics of progeria cells)
was also observed by immunostaining of lamin A/C (inset in
Fig. 4C). At the functional level, both N-iPSC ECs13 and HGPS-
iPSC ECs responded to pro-inflammatory stimuli such as TNF-a
for 24 h leading to an increase in the expression of adhesion
molecules, which then mediated the adhesion of monocytes
(Fig. S3C, ESI†), and hiPSC lines. The derived cells expressed
EC markers at the gene and protein levels and were functional.
Vascular screening of NPs in a 2D model
The impact of the nanomaterial library was evaluated in ECs
derived from N-iPSCs or HGPS-iPSCs cultured in static conditions.
Cells were cultured for 24 h, washed and then exposed for 24 h to
different concentrations of the nanomaterials (6, 12.5, 25 and
50 mg mL1) (Fig. 5A). The effect of the NPs was quantified by
two tests: (i) cell metabolism through the measurement of mito-
chondrial activity by a PrestoBlue assay and (ii) cell necrosis by
counting cell nuclei using a Hoechst 33342/propidium iodide (PI)
staining (Hoechst to quantify the total number of cells; PI to
quantify the dead cells). Because some NPs may interfere with the
PrestoBlue assay,31 cells after being incubated with NPs for 24 h
were washed 3 times with PBS before incubating with PrestoBlue.
These washing steps (which were not necessary and thus not
performed in the Hoechst 33342/PI assay) likely induced higher
cell detachment/loss, especially when NPs cause some toxicity,
which may lead to an apparent low mitochondrial activity. This
might be the reason why the PrestoBlue results appeared to show
more toxic effect for some NPs than the corresponding Hoechst
33342/PI assay. Therefore, primarily, we have used Hoechst/PI
staining to compare all the experimental groups. From the thirty
nanomaterials tested, 7 induced significant toxicity (460% at
50 mg mL1; based on PI staining) towards both hPSC-derived
ECs tested (i.e., NP1, NP3, NP14, NP15, NP18, NP22 and NP30)
whereas 2 nanomaterials (NP25 and NP28) induced significant
toxicity only towards N-iPS ECs (Fig. 5B–E). The high toxicity
observed for NP1 and NP3 NPs (i.e., ultrasmall Au NPs) is in
agreement with previous results obtained in HeLa cells, with a
reported IC50 of about 50 mM.25,32 The toxicity of NP15 (ZnO) is in
line with the toxic profile observed previously in human aortic ECs
(450% for 4 to 24 h incubation at 50 mg mL1),33,34 human cardiac
microvascular ECs (460% for 12 to 24 h incubation at
50 mg mL1)35 and in human umbilical vein ECs (HUVECs)
(475% for 24 h incubation at 32 mg mL1).36,37 Regarding NP28,
the results are also in accordance with those reported in the
literature for HUVECs exposed for 24 h, with toxicities ranging from
20 to 60% for 50 and 75 mg mL1 SiO2 concentrations, respectively.
38
NPs showed a differential toxic effect against both types of
ECs. HGPS-iPSC ECs were more sensitive to NP13, NP18, NP22,
NP26 and NP29 NPs as compared to N-iPSC ECs (Fig. 5B–E).
However, NP3, NP7, NP24, NP25, and NP28 were more toxic for
N-iPSC-derived ECs than for HGPS-iPSC ECs.
To investigate whether the nanomaterial toxicity correlates
with its capacity to be internalized by ECs, we performed
inductively coupled plasma mass spectrometry measurements
(ICP-MS) on N-iPSC ECs and HGPS-iPSC ECs exposed to 11
different nanomaterials (25 mg mL1) for 24 h (Fig. 5F). The
concentration of NPs was selected based on a compromise
between cell death and NP quantification before cell death.
For one of the nanomaterials tested (NP1), the accumulation
was evaluated after 4 h of incubation with cells, because of the
high toxicity observed after 24 h incubation. Overall, our results
Fig. 5 Impact of nanomaterials in iPSC-ECs cultured in 2D. (A) Schematic
representation of the protocol used. Cells were seeded at density of 1 
105 cells per cm2 and were allowed to rest for 24 h, after which NPs were
added in fresh medium at concentrations between 6 and 50 mg mL1 for a
24 h period. Cell viability was evaluated by Hoechst 33342/PI staining,
while cell metabolism was quantified by a PrestoBlue assay. (B) Repre-
sentative images of Hoechst 33342/PI staining for N-iPSC ECs with (NP1 or
NP15, both at 50 mg mL1) or without exposure to NPs for 24 h. Scale bar is
50 mm. (C and D) Heat maps of NP toxicity based on Hoechst 33342/PI
staining (C) and PrestoBlue assay (D; normalized by control cells, without
NPs). (E) Toxicity observed by PI staining in N-iPSC ECs and HGPS-iPSC
ECs exposed to NPs at 25 mg mL1 (E.1) and 50 mg mL1 (E.2). Results are
mean  SEM (n =4). *, **, and **** denote statistical significance (P o 0.05,
P o 0.01, and P o 0.0001). (F) ICP-MS analyses in N-iPSC ECs and HGPS-
iPSC ECs after being exposed to NPs for 24 h (except for NP1, which was
4 h incubation). Results are mean  SEM (n =4). **, ***, and **** denote
statistical significance (P o 0.01, P o 0.001, and P o 0.0001). In E and F,
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indicate that the toxicity of the NPs was not dependent on the
concentration internalized by the cells. For example, NP24,
NP25 and NP30 had similar ranges of cytotoxicity (Fig. 5E.1)
against N-iPSC ECs but significant differences in NP uptake
(Fig. 5F). On the other hand, the cellular uptake of NP1 and NP7
was very low compared to that of other NP formulations;
however, they exerted a higher cytotoxic effect against ECs. In
addition, one (NP12) showed high cellular internalization
(Fig. 5F), mostly by N-iPSC ECs, without showing measurable
toxicity (Fig. 5C). Interestingly, some nanomaterials were more
internalized by HGPS-iPSC ECs than by N-iPSC ECs and this is
surprising taking into account that HGPS-iPSC ECs showed
lower cell doublings than N-iPSC ECs (Fig. S3B, ESI†).
Overall, our results indicate that: (i) NPs showed a differential
toxic effect against both types of ECs and (ii) there is not a direct
correlation between the concentration of NPs internalized by cells
and the observed toxicity in vitro under static conditions.
Regarding this last point, some NPs showed high internalization
efficiency without causing any toxic effect on cells, whereas others
caused high toxicity with very low internalization efficiency.
Vascular screening of NPs in a 3D model
The vascular impact of the NPs was then screened by a Matrigel
assay39 comprising the formation of microvessels with a
patent lumen, as previously demonstrated by us in ref. 12.
The optimization of the assay (e.g. cell exposure time to
nanomaterials, concentration of nanomaterials, and type of
readouts) was carried out with somatic ECs (human umbilical
arterial ECs) (Fig. S4, ESI†). Cells were cultured on top of
Matrigel in the presence of NPs for 24 or 48 h after which EC
viability and tube length was measured. The option of mixing
the NPs during the formation of microvessels, and not after,
was inspired by the in vivo strategy described below in zebrafish
embryos in which the effect of the NPs was evaluated during,
and not after, embryonic vasculature formation. Our results
indicate that cells exposed to NP1 at 1 mg mL1 for 24 h had no
significant effect, while at 12.5 mg mL1 showed approximately
12% and 14% of apoptosis and necrosis, respectively, and were
unable to form vascular microvessels in Matrigel (cells showed
clear altered morphology) (Fig. S4, ESI†). Therefore, for the
screening assay in Matrigel we have used N-iPSC-ECs, at a
concentration of nanomaterials of 12.5 mg mL1 and we evaluated
the length of the microvessels after 24 h (Fig. 6A). Interestingly,
only three formulations could negatively affect microvessel
formation, specifically NP1, NP3 and NP29 that reduced or even
abolished the formation of microvessels (Fig. 6B.1). Interestingly,
NP9 enhanced angiogenesis, as LL37 peptide is a recognized
pro-angiogenic peptide.18
Next, to compare the vascular response in 3D versus 2D (see
section above), we have mixed NP formulations (at a concentration
of 25 mg mL1) with N-iPSC ECs or HGPS-iPSC ECs, cultured the
cells in Matrigel for 24 h and measured cell toxicity by Hoechst/PI
staining. We have selected 6 NP formulations for these analyses
including NP1, NP3, NP4, NP14, NP15 and NP29 since they
showed cytotoxicity in a 2D model (Fig. 5C). The toxicity levels
(based on PI staining) of NP1 and NP3 were lower than the ones
observed in a 2D model (NP1: 60 vs. 90%; NP3: 40 vs. 90%, all
based in N-iPSC ECs); however, it was higher for NP29 (N-iPSC
ECs: 20 vs. 10%; HGPS-iPSC ECs: 40 vs. 20%). Our results further
showed differences in NP toxicity against N-iPSC ECs and HGPS-
iPSC ECs (Fig. 6C). For example, NP4 and NP14 induced higher
toxicity towards N-iPSC ECs than HGPS-iPSC ECs. In contrast,
NP29 induced higher toxicity towards HGPS-iPSC ECs than N-iPSC
ECs, similar to the results obtained with the 2D model (Fig. 5).
Previous studies have shown that the accumulation of progerin
in ECs induced a pro-inflammatory program of EC activation
characterized by an overexpression of leukocyte adhesion mole-
cules (VCAM1, E-selectin)40 and pro-inflammatory cytokines (IL8)40
and a downregulation of the transcription factor Kruppel-like
factor (KLF2),40 which regulates EC pro-inflammatory activation,
but also a decrease in the anti-oxidative stress response program
Fig. 6 Impact of nanomaterials on iPSC-ECs cultured in 3D. (A) Schematic
representation of the protocol to evaluate the effect of NPs in the
formation of capillary-like networks by iPSC-ECs on Matrigel. Cells were
seeded on top of Matrigel at a density of 2 103 cells per well together with
NPs (12.5 mg mL1) for 24 h, after which cell viability and tube formation was
analyzed. (B.1) Impact of NP library on the length of microvessels formed by
N-iPSC ECs. Results are average  SEM (n = 4). **, and **** denote
statistical significance (P o 0.01, and P o 0.0001, respectively) relative to
control. (B.2) Representative images of capillary-like networks formed in
Matrigel by N-iPSC ECs treated for 24 h with 12.5 mg mL1 of NP1, NP9 or
without NPs (control). Scale bar is 200 mm. (C) Toxicity was measured by
Hoechst 33342/PI staining at 24 h, in HGPS-iPSC ECs or N-iPSC ECs
cultured in the presence of NP1, NP3, NP4, NP14, NP15 and NP29 in
Matrigel at 25 mg mL1. *, ***, and **** denote statistical significance (P o
0.05, P o 0.001, and P o 0.0001). (D) Relative gene expression of genes
involved in oxidative stress (NRF2), inflammation (ICAM1, SELE, VCAM1 and
IL8) and endothelial homeostasis (KLF2, and VEGF) in N-iPSC ECs and
HGPS-iPSC ECs before (D.1) and after exposure to 25 mg mL1 of NP29
(D.2) or NP14 (D.3). *, **, and *** denote statistical significance (P o 0.05,
P o 0.01, and P o 0.001). In B.1, C and D, the statistical analyses were
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characterized by an impaired transcriptional activity of the
transcription factor NRF2.41 Indeed, HGPS-iPSC ECs have higher
reactive oxidative species levels than N-iPSC ECs (Fig. S5, ESI†). To
identify the mechanism behind the differential toxicity of NPs
against N-iPSC ECs and HGPS-iPSC ECs, we evaluated the expres-
sion of genes involved in oxidative stress (NRF2), inflammation
(SELE, ICAM1, VCAM1 and IL-8) and endothelial homeostasis
(KLF2, and VEGF) in cells exposed to NP14 and NP29 (both at
25 mg mL1) for 24 h (Fig. 6D). In the absence of NPs, HGPS-iPSC
ECs showed higher expression of inflammatory and oxidative
stress but lower KLF2 mRNA transcripts than N-iPSC ECs. After
exposure to NPs, the inflammatory response of both cells was
significantly different: only N-iPSC ECs showed a significant
up-regulation of pro-inflammatory mRNA and the response
seemed higher for NP14 than for NP29. Moreover, N-iPSC ECs,
but not HGPS-iPSC ECs, showed an upregulation of mRNA of the
NRF2 gene that encodes nuclear factor erythroid 2-related factor
involved in the cellular antioxidant response. Altogether, our
results indicate that: (i) a small number of NPs (3 out of 30)
interfered with microvessel formation in Matrigel at the con-
centration tested (12.5 mg mL1); (ii) the Matrigel assay showed
differences in the vascular toxicity profile (evaluated by PI staining)
of NPs relative to the 2D model, but in both cases the importance
of EC background was critical for the biological response; (iii) the
differential biological response of N-iPSC ECs and HGPS-iPSC ECs
to NPs involved differential regulation of genes related with
inflammation and oxidative stress.
Screening of NPs in a blood vessel on a chip
The vascular models described above have several limitations,
including the fact that they are not perfused and do not take
into account the heterotypic interactions between ECs and
SMCs. Cells exposed to flow change their morphology and more
importantly they express a layer of proteins, glycoproteins, glyco-
lipids, proteoglycans and glycosaminoglycans called glycocalyx.42
The glycocalyx is involved in several functions, such as regulation
of vascular permeability, acting as a selective barrier to macro-
molecules (based on size and charge), as well as a mechanosen-
sor of fluid shear stress. Thus, we decided to prepare a blood
vessel on a chip to screen nano–bio interactions. In general, these
chips have only one layer of endothelial cells to evaluate nano–
bio interactions.43 Here, we have successfully developed a chip
with two-cell monolayers of SMCs and ECs. The vessel was
perfused with medium, at shear rates similar to in vivo, and the
EC monolayer was able to secrete a functional glycocalyx layer on
top. For this purpose, SMCs (for initial studies we have used
somatic cells) were cultured in a microfluidic chamber for 12 h to
form a monolayer followed by the plating of ECs on top of SMCs
for 4 h and finally by the perfusion of both cells for 5 days
(Fig. S6, ESI†). Under these conditions, SMCs were in the outer
part of the vessel, while ECs remained in the luminal side
(Fig. S6A and B, ESI†). Interestingly, ECs co-cultured with SMCs
under flow conditions showed higher levels of glycocalyx than
ECs alone cultured under flow conditions (Fig. S7A, ESI†). To
verify that the glycocalyx was indeed located in the luminal side
of ECs, we have used GFP-expressing ECs, which were co-cultured
with SMCs for 5 days under flow as previously described
(Fig. S7B and C, ESI†). As expected, the layer of glycocalyx was
located on top of the EC layer in the luminal side, showing the
polarization of the glycocalyx. The formation of the glycocalyx was
also demonstrated by an EC uptake assay of DiI-LDL (Fig. S7D, ESI†).
In this case, cells cultured under flow conditions for 5 days had
lower uptake of Dil-LDL than cells cultured for 5 days and exposed to
heparinase III to remove the heparin sulfate in glycocalyx.
In order to verify the effect of flux in the formation of glycocalyx,
SMCs and ECs were co-cultured as previously described and the
heparan sulfate intensity was quantified at different time points
(Fig. S8A, ESI†). The amount of heparan sulfate increased more
than 2.5-fold up to 5 days in flow, at 20 dyn cm2 (Fig. S8B and C,
ESI†). The recovery of heparan sulfate was also evaluated. Cells
cultured under flow for 5 days were treated with heparinase III to
degrade the heparan sulfate, and its recovery was followed over
time (Fig. S8D, ESI†). The kinetics of the recovery was similar to
the one observed for the heparan sulfate formation induced
by the shear stress. Therefore, for subsequent experiments
with iPSC-derived cells, they were co-cultured for 5 days at
20 dyn cm2. We performed experiments with N-iPSC SMCs
and N-iPSC ECs (Fig. 7A) but not with HGPS-iPSC-derived cells
because the HGPS-iPSC SMCs were sensitive to flow and
detached overtime.44 N-iPSC SMCs obtained using protocols
previously published by us in ref. 45 were cultured in a micro-
fluidic chamber followed by the culture of N-iPSC ECs on top
of the SMCs (Fig. 7B). Cells were then cultured under flow
conditions (20 dyn cm2) for 5 days. Under these conditions,
N-iPSC SMCs were located in the outer part of the blood vessel
and positively stained for a-smooth muscle actin (a-SMA)
whereas the iPSC-ECs, which were located in the inner part of
the blood vessel, were positively stained for VE-cadherin
(Fig. 7B.1). As expected, ECs expressed glycocalyx, the expression
being higher in flow than in static conditions (Fig. 7B.2) and in
co-culture with SMCs versus ECs alone (Fig. 7C). Moreover, the
enzymatic removal of heparan sulfate by heparinase in vascular
cells cultured under flow conditions for 5 days allowed higher
accumulation of Dil LDL (Fig. 7D) than cells without enzymatic
treatment. Altogether, we have developed a blood vessel on a
chip from ECs and SMCs derived from iPSCs. ECs co-cultured
with SMCs under flow conditions expressed higher levels of
heparan sulfate than ECs cultured in static conditions and thus
represent a better match to the in vivo blood vessel physiology.
Next, we have tested the 10 NPs identified in previous
vascular models with higher cytotoxicity effects in a blood
vessel on a chip (Fig. 7E). In this model, we used ECs and
SMCs derived from N-iPSCs. Ten NPs were exposed for 24 h
under flow conditions to the blood vessel on a chip. For two of
the formulations (NP15 and NP25) we have also quantified the
cellular internalization of the NPs by ICP-MS analyses. The
results show that NP internalization was 34.6 pg per cell and
1.1 pg per cell (assuming that all the NPs were taken up by ECs
alone) of NP15 and NP25, respectively, which means approxi-
mately 3-fold lower than in static conditions (Fig. S9, ESI†).
Interestingly, all the NPs tested showed lower toxicity than in
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toxicity may be explained by the protective role of glycocalyx
expressed in the blood vessel on a chip. To demonstrate this
hypothesis, the toxicities of NP1 and NP2 were evaluated in 3
different models: (i) a co-culture of N-iPSC SMCs and N-iPSC
ECs (Fig. 7G), (ii) a monoculture of N-iPSC ECs (Fig. 7H.1) and
(iii) a monoculture of N-iPSC SMCs (Fig. 7H.2). As shown before
(Fig. 7C and Fig. S7A, ESI†), a co-culture of SMCs and ECs led to
an increase of the production of the glycocalyx layer shown by a
significant increase in intensity of heparan sulfate, one impor-
tant and main component of the glycocalyx. Our results showed
that when ECs had this protective glycocalyx layer the toxicity of
NP1 was considerably lower than in cells without this layer
(Fig. 7G). In addition, when the glycocalyx layer was impaired,
either by enzymatic degradation (Fig. 7G) or by using the
monoculture cell model of ECs (that produces less glycocalyx;
Fig. 7H.1), the toxicity was higher relative to cells with a
glycocalyx layer. iPS-SMCs showed no toxicity towards these
NPs at the concentrations tested (Fig. 7H.2). Therefore, the
presence of a glycocalyx layer influenced the impact of NPs on ECs
and might explain differences in the toxicities of nanomaterials in
static vs. flow conditions.
Overall, our results indicate that most of the nanomaterials
that had a negative impact on the angiogenesis of blood vessels
in the transgenic zebrafish model showed vascular toxicity in
the 2D and 3D models but with differences according to the
type of vascular cells and their organizational complexity. In
addition, the toxicities of the tested NPs were lower in the blood
vessel on a chip than in the 2D model. The results further
indicate that the decrease in the NP toxicity, at least in part, was
mediated by the expression of a protective glycocalyx layer in
ECs cultured in the blood vessel on a chip.
3. Discussion
The current work describes a platform to study the bioactivity/
toxicity of nanomaterials based on vascular cells derived from
hiPSCs, which were cultured in 3 different platforms with
increasing level of complexity: (i) monoculture in poly(styrene)
(named ‘‘2D’’); (ii) monoculture in Matrigel (named ‘‘3D’’) and
(iii) co-culture (both ECs and SMCs) under flow conditions
(named ‘‘blood vessel on a chip’’). These 3 platforms captured
different aspects of the impact of the nanomaterials and the
results were validated in zebrafish embryos, more specifically, in
the capacity of the NPs to interfere with embryonic vasculogenesis.
The 2D model is the most suitable model for high-throughput
screening; however, it does not recapitulate the three-dimensional
organization of the blood vessel as well as the dynamic environ-
ment of the bloodstream, which may induce phenotype alterations
in ECs (e.g. absence of glycocalyx expression) and NPs may deposit
at higher levels onto the cells, which increases NP uptake. The
3D model is suitable to reproduce the geometry of the blood
vessel in vitro since ECs associate into 3D tubes with lumen
formation;12,39 however, as a 2D model, it does not take into
account the complexity of the blood vessel or the effect of flow.
The blood vessel on a chip is suitable to reproduce the
Fig. 7 Impact of nanomaterials in a blood vessel on a chip composed by
iPSC-ECs and iPSC-SMCs. (A) Protocol to generate a blood vessel on a chip. A
suspension of SMCs (4.1 104 cells per cm2) was applied in each channel of an
Ibidi m-Slide VI0,4 plate. SMCs were maintained in static conditions for 12 h, after
which a suspension of ECs (12.5  104 cells per cm2) was applied on top of
SMCs and the co-culture was maintained in static conditions for 4 h, after
which cells were perfused with EGM-2 medium at 20 dyn cm2 for 5 days.
(B) Immunofluorescence analyses performed on a co-culture of N-iPSC SMCs
and N-iPSC ECs for: SMC (a-SMA), EC (VE-cadherin) (B1) and glycocalyx
(heparan sulfate) (B2) markers. Scale bar is 50 mm. (C) Heparan sulfate intensity
in a co-culture of N-iPSC SMC and N-iPSC EC cells vs. monoculture of N-iPSC
ECs after 5 days under arterial flow conditions (20 dyn cm2). **** denotes
statistical significance (P o 0.0001). (D) Effect of glycocalyx impairment (by
heparinase III treatment) on the uptake of DiI-LDL by N-iPSC ECs after 5 days in
co-culture with N-iPSC SMCs under arterial flow conditions (20 dyn cm2).
**** denotes statistical significance (P o 0.0001). In C and D, the statistical
analyses were performed by an unpaired t-test. (E) Schematic representation of
the protocol. Cells (co-culture of N-iPSC SMCs and N-iPSC ECs) were cultured
for 5 days in arterial flow conditions (20 dyn cm2), after which NPs were
incubated for 24 h and characterized for cell metabolism and death. (F) Cell
viability after 24 h incubation in flow conditions measured by Hoechst 33342/PI
staining. Arrows show the difference in toxicity between static (monoculture of
N-iPSC ECs) and flow conditions (co-culture N-iPSC SMCs and N-iPSC ECs)
for the same NPs. Results are mean  SEM (n = 4–6). *, and **** denote
statistical significance (P o 0.05, and P o 0.0001) against control (cells without
NPs). (G) Effect of the removal of endothelial glycocalyx, by heparinase III
treatment, on the metabolism of N-iPSC ECs and N-iPSC SMCs cultured in the
microfluidic chip for 24 h with NP1 or NP2. ** denotes statistical significance
(P o 0.01) against control (cells without NPs). (H.1) Cell metabolism of N-iPSC
ECs after 24 h incubation with NP1 or NP2 under arterial flow conditions.
**** denotes statistical significance (P o 0.0001) against control (cells without
NPs). (H.2) Cell metabolism of N-iPSC SMCs after 24 h incubation with NP1
or NP2 under arterial flow conditions. In F, G and H, results are mean  SEM
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complexity (as it includes ECs and SMCs) and flow culture
conditions as observed in the in vivo blood vessels; however, it
is complex for use in high-throughput screening. Our results
indicate that the three platforms were able to identify, to
different extents, the NPs that showed toxicity against zebrafish
embryos. From the 18 NP formulations that interfered with the
vasculogenesis process in zebrafish embryos (Fig. 3), 15 NP
formulations have been identified by the in vitro models (2D and
3D models; the number of PI+ cells was above 20%), their
toxicity level being dependent on the hiPSC-EC type. Some of
the formulations were also tested in the blood vessel on a chip
and the results further confirmed their toxicity; however, in
general, at lower intensity. Table S1 (ESI†) summarizes the main
findings obtained among the four systems as well as rodent data
found in the literature.
Previous studies have used 2D models based on somatic
ECs, but not on ECs derived from hiPSCs generated from
different individuals, to screen multiple NP formulations.46 In
addition, hiPSC-ECs have been used to screen small molecules12
but not nanomaterials. The use of hiPSCs enables the in vitro
modelling of different individuals with or without diseases. The
development of iPSC technology allows the access of a virtually
unlimited number of cells from any individual, which can then
be differentiated into any kind of cells and be used for high-
throughput screening studies. This technology has allowed, for
instance, the screening of large libraries of small compounds to
find hits that rescue genetic diseases47,48 or interfere with
human development.12 We have used hiPSCs as a source of
ECs to study nanomaterial interactions, which have not yet been
investigated. We have studied the impact of nanomaterials on
hiPSC-ECs having embryonic (N-iPSC ECs)12 and aged pheno-
types (HGPS-iPSC ECs), as confirmed by the accumulation of
progerin and the existence of dysmorphic nuclei in the latter.
The selection of HGPS-iPSC ECs in the context of this work was
to investigate the biological response of aged cells to NPs, which
is a topic that remains largely unexplored.
Our results indicate that HGPS-iPSC ECs and N-iPSC ECs
had differential toxicity profiles against NPs, both in 2D and 3D
models. The ultrasmall NP1 and NP3 were shown to be the
most toxic of all NPs of the library for both types of ECs, even
for concentrations at 6 mg mL1 (2D model); five NPs (NP14,
NP15, NP18, NP22 and NP30) showed toxicity levels higher than
60% (measured by a PI assay) for both EC-derived cells; three
NPs (2D system: NP25 and NP28; 3D system: NP14) showed
higher toxicities against N-iPSC ECs than HGPS-iPSC ECs; one
NP formulation (NP29) showed higher toxicity (3-fold) for
HGPS-iPSC ECs than for N-iPSC ECs. The vascular toxicities
observed for some NPs in the 2D model are in good accordance
with those reported in the literature using somatic cells. For
example, NP1 and NP3 showed high toxicities against HeLa
cells.32 Zinc oxide NPs were observed to be toxic (450%) at
50 mg mL1 in human aortic ECs,34 human cardiac microvascular
ECs35 and in HUVECs;36,37 all these results are in good accor-
dance with the 60% toxicity observed in our study for ECs
derived from iPSCs. SiO2 NPs have also been reported to induce
toxicities from 20 to 60% in HUVECs for NP concentrations
between 50 and 75 mg mL1,38 while Ag NPs have been reported
to induce toxicity in rat brain microvessel ECs49 and to demon-
strate anti-angiogenic properties.50 It is possible that the higher
toxicity of Ag NPs against HGPS-iPSC ECs, as compared to that
of N-iPSC ECs, is related to a decrease in the antioxidative stress
response program in HGPS-iPSC ECs. It is known that Ag NPs
induce cytotoxicity through oxidative stress, leading to the
production of reactive oxygen species (ROS) in their surface
or though the direct interaction with cell mitochondria.51 On
the other hand, the nuclear accumulation of progerin impairs
the transcriptional activation of NRF2, due to the physical
interaction of both proteins, which reduces the anti-oxidative
stress program of HGPS cells.41 Therefore, it is expected that
HGPS-iPSC ECs are more sensitive to NPs that induce toxicity by
oxidative stress such as Ag NPs. In contrast, the higher toxicity
of NP14 against N-iPSC ECs as compared to HGPS-iPSC ECs
may be related to the differential inflammatory program
between cells. Our results show that HGPS-iPSCs have a pro-
inflammatory program before NP exposure, characterized
by higher levels of VCAM1, SELE, IL8 and ICAM1 mRNA
transcripts as compared to N-iPSC ECs. It is possible that the
pro-inflammatory status of HGPS-iPSC ECs makes these cells
less sensitive to inflammatory cytokines than N-iPSC ECs.
Indeed, the pro-inflammatory program of HGPS-iPSC ECs is
not significantly affected after exposure to NPs, while the
opposite was observed in N-iPSC ECs.
The EC response to NPs is largely influenced by the flow
shear stress and the interaction with SMCs. EC genotype/
phenotype as well as endocytic capacity are influenced by flow
shear stress. For example, ECs cultured under increased shear
stress have decreased oxidative stress and inflammation52 and
showed differential NP uptake as compared to ECs cultured
under static conditions.43,53 Importantly, EC response to flow
shear stress is influenced by the neighbouring SMCs.54,55
Although in vitro co-culture systems of ECs and SMCs under
flow conditions have been established for somatic ECs and
SMCs,54,55 the generation of co-culture systems with hiPSC-derived
vascular cells remains unexplored. The model developed in the
current work allows the performance of assays at arterial
conditions by submitting cells to shear stresses of 20 dyn
cm2. In this model, cells aligned parallel to the flow direction,
and ECs produced a glycocalyx (a glycoprotein–polysaccharide
meshwork) layer in the apical region as it occurs in vivo.
Previous studies have shown that glycocalyx influences NP
uptake by somatic ECs.56,57 Our results showed that NP toxicity
against ECs is significantly lower in cells cultured under flow
conditions and in co-culture with SMCs. Our results further
showed that glycocalyx mediated, at least in part, the reduction
in NP internalization, since the degradation of glycocalyx by
heparinase significantly reduced cell metabolism/viability.
In many cases, the impact of nanomaterials is screened in
rodents;4–6 however, these experiments are expensive, time
consuming and low throughput. Zebrafish embryos can be
used to investigate vascular toxicity of NPs because they are
relatively cheap, the developmental processes are well studied
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transgenic lines with fluorescent markers.58,59 Therefore, in the
current work, zebrafish embryos were used to validate the
toxicity profiles of the NP library evaluated in the in vitro tests.
Because some NPs are trapped by the chorion of zebrafish,60 we
have removed it to perform the screening. Our results showed
that 18 NP formulations had an impact in the angiogenesis of
the intersegmental vessels of zebrafish embryos. Most of the
formulations (15 out 18) were confirmed by the in vitro tests.
The iPSC-derived vascular networks described here might be
useful to screen other types of nano–bio interactions. For
example, recent studies have shown that some NPs can disrupt
the VE–cadherin interactions between endothelial cells (called
nanoEL effect), negatively charged NPs being the ones with the
highest impact.9,61 For this purpose, we have tested the effect of
silica NPs (formulation NP13) in a monolayer of N-iPSC ECs for
1 h after which we have evaluated its paracellular permeability
against FITC–dextran and VE–cadherin interaction between
cells by confocal microscopy (Fig. S10, ESI†). Our results clearly
show the sensitiveness of our iPSC-derived vascular network to
the nanoEL effect.
4. Conclusions
We have developed personalized human in vitro platforms with
a variable level of complexity (2D, 3D and blood vessel on a chip
formats) and ageing phenotype to evaluate the interaction of
nanomaterials with the vascular system. Taking into account
the toxicity as the main readout, the NP toxicity profile was
dependent on the age and vascular network format, the NPs
being less cytotoxic in the blood vessel on a chip format due to the
protective effect of glycocalyx. The platform presented here is very
promising for high-throughput screening of nano–bio interactions
in the context of regenerative and therapeutic medicine.
5. Experimental section
Nanomaterial library: characterization
The diameter and morphology of some of the nanomaterials
were characterized using a PHILIPS CM-12 transmission electron
microscope at 100 kV. A few microliters of an aqueous suspension
of nanomaterials was placed on a 200-mesh copper grid coated
with a Formvar film and then wiped off by filter paper. The dried
grid was then examined under an electron microscope. Addition-
ally, the nanomaterials were analysed by photon correlation
spectroscopy (PCS) using quasi-elastic light scattering equipment
(Zeta-Palst Zeta Potential Analyzer, Brookhaven Instruments
Corp., Holtsville, NY) and the ZetaPlust Particle Sizing Software
(version 4.03). The nanomaterial suspension (2 mL, 50 mg mL1 in
PBS or EGM-2 medium containing FBS) was added to a cuvette and
allowed to stabilize for 10 min and then analysed (3 times)
at room temperature. Nanomaterials suspended in EGM-2
medium were then centrifuged (8000g, 8 min) and resuspended
in 1 mM KCl (2 mL, 50 mg mL1), at 25 1C. The nanomaterial
suspension was finally characterized by zeta potential analyses.
All data were recorded with at least 5 runs (in triplicate) with a
relative residual value (measure of data fit quality) of 0.03.
In vivo studies
Zebrafish (Danio rerio) were maintained in accordance with
Institutional and National Animal Care protocols, in a re-circulating
system at 28 1C on a 14 h-light, 10 h-dark cycle, fed twice daily.
Transgenic adult zebrafish [Tg(fli1a:EGFP)y1]26 expressing enhanced
green fluorescent protein (EGFP) under control of the fli1 promotor
were used in this work. Genders were housed separately until the
day before breeding, then placed in tanks at a 2 : 1 male : female
ratio. Fish were left undisturbed overnight and fertilized embryos
were collected 4 hours after the light was turned on the next
morning. For each condition, a minimum of 20 embryos within 4
hours-post-fertilization (hpf) were manually dechorionated and
randomly placed in glass Petri dishes containing 10 mL of embryo
medium. NPs at 1 mg mL1 were added to the embryo medium and
incubated for 24 hours, after which the embryos were fixed with 4%
PFA at 4 1C overnight. Embryos were then washed twice with PBS. As
a control, the same amount of vehicle (water) was used. For each
experimental group a minimum of eight embryos were analysed for
the number of ISVs along the anterior–posterior axis, the average
length of the first 10 ISVs and the total length of ISVs. Different
batches of embryos and pools of embryos from different mating
pairs were used among different experiments. Images of the embryos
embedded in 3% carboxymethyl cellulose were obtained using a
Zeiss/P.A.L.M. laser dissecting microscope equipped with a Fluar 5/
0.25 M27 objective. The number and length of ISVs were directly
measured in each image by the same user using ImageJ software.
iPSC culture
HGPS-iPS cells were generated from skin fibroblasts of an
HGPS patient and were kindly donated by Xavier Nissan.15
N-iPSCs were generated from cord blood (hiPSCs K2, passages
32–35)62 and were kindly donated by Ulrich Martin. Cells at
passage 35–45 have been used for the differentiation studies.
Both iPSCs were cultured on inactivated mouse embryonic
fibroblasts (MEFs), as previously described.12,13,45
iPSCs: differentiation into SMCs
The differentiation of iPSCs into SMCs was performed through
an intermediary embryoid body (EB) stage. Undifferentiated
iPSCs were treated with type IV collagenase (2 mg mL1,
Invitrogen) for 2 h and then transferred (2 : 1) to low attachment
plates (Corning) containing a differentiation medium [10 mL, 80%
KO-DMEM, 20% FBS, 0.5% L-glutamine, 0.2% b-mercaptoethanol,
1% nonessential amino acids and 50 U mL1 : 50 mg mL1
penicillin–streptomycin solution] to form EBs. EBs were cultured
for 10 days at 37 1C, 5% CO2 in a humidified atmosphere, with
medium changes every 3–4 days. CD34+ cells were isolated from
EBs at day 10 using magnetism-activated cell sorting (MACS).
Isolated cells were grown on 24-well plates coated with 0.1%
gelatin and containing endothelial growth medium-2 (EGM-2)
supplemented with retinoic acid (1 mM, Sigma).
iPSCs: differentiation into ECs
Undifferentiated iPSCs were treated with type IV collagenase
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dishes coated with fibronectin (1 mg cm2, Calbiochem) and
containing a differentiation medium [10 mL of 50% Iscove’s
modified Dulbecco’s medium (IMDM, Gibco), 50% F12 (Gibco),
5 mg mL1 BSA (Sigma), 0.2% b-mercaptoethanol, 15 mg mL1
transferrin (Sigma), 7 mg mL1 Insulin (Sigma) and 50 U mL1
penicillin–streptomycin (Lonza)]. The differentiation medium
was supplemented with BMP4 (10 ng mL1, Peprotech) and
FGF-basic (20 ng mL1, Peprotech). After 1.5 days, the medium
was replaced with fresh differentiation medium supplemented
with BMP4 (50 ng mL1) and FGF-basic (20 ng mL1). After
5 days, the medium was further replaced by fresh differentiation
medium supplemented with VEGF165 (50 ng mL
1, Peprotech),
Tb4 (100 ng mL1, Caslo) and SB431542 (10 mM, Tocris). At the
end of day 10, the PECAM1+ cells were selected by magnetic
labelling, plated in 0.1% gelatin-coated dishes and cultured with
EGM-2 medium supplemented with VEGF165 (50 ng mL
1) and
SB431542 (10 mM). The medium was changed every 2–3 days.
Primary vascular cell culture
Human vascular smooth muscle cells (Lonza, CC-2579) were
cultured in MCDB 131 medium (Gibco) supplemented with FBS
(20% v/v, Gibco), L-glutamine (Gibco, 1 mM) and penicillin–
streptomycin (50 U mL1, Lonza). Human umbilical artery
endothelial cells (HUAECs) and human umbilical vein endothelial
cells (HUVECs) were cultured in EGM-2 (Lonza). Cell cultures were
maintained at 37 1C, and 5% CO2 in a humidified atmosphere,
with media changed every 2 days.
Cell characterization: immunofluorescence analyses
Cells were washed with PBS, fixed with 4% paraformaldehyde
(Electron Microscopy Sciences) for 15 min at room temperature
and washed again with PBS. Cells were permeabilized (when
necessary) with 0.1% Triton for 10 min, blocked with 1% (w/v)
BSA for 30 min and incubated for 1 h with specific primary
antibodies: mouse anti-human heparan sulfate (10E4 epitope,
US Biological), rabbit anti-human smooth muscle a-actin
(Abcam), mouse anti-human calponin (calponin1, Santa Cruz
Biotechnology), mouse anti-human PECAM1 (clone JC70A,
Dako), mouse anti-human VE-Cadherin (Santa Cruz Biotechnology),
rabbit lamin A/C (H-110, Santa Cruz Biotechnology) and rabbit anti-
human ZO-1 (Life Technologies). The binding of primary antibodies
was detected with: goat anti-rabbit IgG Alexa 488, goat anti-mouse
IgG Alexa 488 or goat anti-mouse IgG Alexa 555 (Life Technologies).
Cell nuclei were stained with 40,60-diamidino-2-phenylindole (DAPI,
Sigma) and the slides were examined using an LSM 710 confocal
microscope (Zeiss) or a high-content fluorescence microscope IN
Cell 2200 (GE Healthcare). In the case of heparan sulfate immuno-
staining, the imageJ software was used to quantify the overall
intensity of heparan sulfate normalized by the area of the image
in, at least, 8 images per condition.
Cell characterization: flow cytometry analyses
Cells were dissociated with non-enzymatic cell dissociation
buffer (Gibco) for 10 min, followed by gentle pipetting and
washes in PBS with 5% FBS. Single cells were aliquoted in PBS
with 5% FBS (between 100 000 and 150 000 cells were used per
condition) and stained with either isotype controls or antigen-
specific fluorescent-conjugated antibodies for 30 min at 4 1C. The
following antibodies have been used: PECAM1 (eBioscience,
5 mL per 100 mL of cell suspension), CD105 (Miltenyi Biotec,
10 mL per 100 mL of cell suspension) and VEGFR2 (R&D Systems,
10 mL per 100 mL of cell suspension). The flow cytometry analyses
were performed in a BD Accuri C6 and data analysis was
performed with the FlowJo_V10. Ten thousand events were
collected in each run. The percentages shown in dot plots were
calculated based on the isotype controls represented by light
blue. Isotype controls had 1% overlap with the protein of interest.
Cell characterization: ROS levels
N-iPSC ECs and HGPS-iPS ECs were plated in a 96-well plate at a
density of 2  104 cells per well and cultured for 24 h before
incubation with 5 mM CellROXs Deep Red (Invitrogen) for 2 h.
Cells were then washed, fixed with 3.7% formaldehyde for
15 min at room temperature and washed two times with PBS.
Images were taken from each well (9 images per well) using the
IN cell Analyzer 2200 (IN Cell 2200, GE Healthcare) and
analysed using the Analyzer Workstation software. For oxidative
stress measurements the mean intensity of CellROXs Deep Red
was registered in both the cell nucleus and cytoplasm. The total
value of the measured intensity was used and normalized
according to cell area. Assays were performed in triplicate.
Cell characterization: quantitative real-time polymerase
chain reaction (qRT-PCR) analyses. Total RNA was extracted with
an RNeasy Micro Kit (Qiagen) and immediately stored at 80 1C.
RNA was quantified using a NanoDrop ND-1000 spectrophoto-
meter (NanoDrop Technologies, Inc., USA) at 260 nm. The cDNA
was reverse transcribed from 1 mg of total RNA using a TaqMan
reverse transcription reagents kit (Invitrogen) according to the
manufacturer’s instructions. The cDNA obtained was stored at
20 1C until further analysis by real-time PCR was performed.
Real-time PCR analyses were performed using the fluorescent
dye SYBR Green (Applied Biosystems) or TaqMan technology
(Life Technologies) and the 7500 Fast Real Time PCR System
(Applied Biosystems). Specific set of Taqman MGB probe (Life
Technologies) and primers (designed by Sigma) used in this
work (Tables 2 and 3).
Table 2 Set of primers (Sigma) and probe (Life Technologies) for progerin (TaqMan technology) used in this work
Probe Sense Antisense
CGCTGAGTACAACCT ACTGCAGCAGCTCGGGG TCTGGGGGCTCTGGGC
TaqMan PCR conditions: initial step at 50 1C for 2 min; after that another step at 95 1C for 10 min; 45 cycles at 95 1C for 15 s and at 60 1C for 1 min.
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Cell characterization: monocyte-EC adhesion assay
THP1 (1  106 cells per mL) was incubated with CFSE (5 mM,
Molecular Probes) for 15 min at 37 1C and washed three times
in the culture medium to remove the unbound dye at the ratio
of 1 : 2 for 30 min. iPSC-derived ECs were cultured in 24-well
plates until confluence. The cells were then treated with 10 nM
TNF-a (Peprotech), a pro-inflammatory cytokine, for 6 h. Next,
the cells were washed 3 times in the culture medium and
co-cultured with CSFE-labeled THP1 monocytes. Then, the cells
were washed 3 times with PBS to remove unbound THP1 cells,
the nuclei were stained with Hoechst (Molecular Probes), and
the images were acquired using an InCell Analyser HCA System
(GE Healthcare) and analyzed by the corresponding software.
For non-treated and TNF-a-treated cells the percentage of
THP1 cells was calculated relative to the total number of nuclei
counted for each field. Each condition was performed in triplicate
and a minimum of 9 fields were acquired for each well; on average
500 cells were counted per field.
Culture of vascular cells in flow conditions
A suspension of SMCs (derived from N-iPSCs or somatic human
SMCs, 30 mL in MCDB 131 medium, in order to have 4.1 
104 cells per cm2) was applied in each channel of an Ibidi plate
(m-Slide VI0,4 Luer, Ibidi) and allowed to flow inside by capillary
force. After 1 h, each channel was filled with MCDB 131 medium.
The cells were maintained in static conditions at 37 1C, and 5%
CO2 in a humidified atmosphere for 12 h, after which a suspension
of ECs (N-iPSC ECs or HUAECs, and 30 mL of EGM-2 medium, in
order to have of 12.5  104 ECs per cm2) was applied on top of
SMCs. After 1 h, each channel was filled with EGM-2 medium, and
the cells were maintained at 37 1C, and 5% CO2 in a humidified
atmosphere for 4 h in static conditions. After 4 h, the cells were
perfused with EGM-2 medium at the physiological flow rate
(20 dyn cm2) using an Ibidi pump system.
Cell characterization: heparan sulfate analyses
ECs co-cultured with SMCs in a microfluidic system for 5 days
were characterized for the expression of heparan sulfate. Cells
were stained with heparan sulfate (10E4 Epitope, USBiological)
and the overall intensity of heparan sulfate of each image was
quantified using ImageJ software. In a parallel experiment, cells
were treated with heparinase III (Flavobacterium heparinum
0.5 U mL1, Sigma) for 30 min and washed with EGM-2
medium. Cells treated with heparinase were then exposed to
low density lipoprotein from human plasma complexed with
DiI (DiI LDL, Invitrogen) at 20 mg mL1 at 37 1C for 4 h. Cells
were then washed and maintained with medium. Images were
acquired using an InCell Analyser HCA system and analysed
using the corresponding software.
Nanomaterials library: preparation
The following nanomaterials have been used: zinc oxide (Product
Number: 8410DL, SkySpring NanoMaterials), Agions silver anti-
microbial type AJ (Product Number: AJ10D, Sciessent LLC), silicon
oxide (Product Number: 6807NM, SkySpring Nanomaterials, Inc.),
silicon dioxide (Product Number: PL-SiOF, Plasmachem), titanium
oxide (Product Number: 7910DL, SkySpring Nanomaterials, Inc.),
Molday ION MI-750 (Product Number:CL-50Q01-6A-53, BioPAL),
micromers-greenF 25 nm-NH2 (Product Number: 29-01-251),
micromers-greenF 25 nm-COOH (Product Number: 29-02-251),
micromers-greenF, 100 nm-NH2 (Product Number: 29-01-102)
and micromers-greenF 100 nm-COOH (Product Number: 29-02-
102, Micromod Partikeltechnologie GmbH). The nanomaterials
including 1.4MS–Au NPs, 1.5GSH–Au NPs, 12GSH–Au NPs,
13.9MS–Au NPs and 15MS–Au NPs were provided by the Ulrich
Simon group and the synthesis and characterization have been
reported elsewhere.25,63,64 PLGA,20 PLGA–PS,20 CM–AuNPs,19
LL37–AuNPs,18 PEI:DS,21 PEI–DMNC,24 A1,22 A9,22 C11,22 E1,22
E2,22 P1C5,23 and P1C723 have been synthesized by us and the
synthesis protocols were previously published. 5HA–Au NPs
were obtained by ligand exchange of 1.4MS–Au NPs with thiol
end-modified HA. 20HA–Au NPs were obtained by ligand
exchange of citrate–Au NPs (10 nm) with thiol end-modified
HA. Thiol end-modified HA was obtained by reductive amination.
Briefly, HA (MW 8–15 kDa, 100 mg) and cystamine dihydrochloride
(60 mg) were dissolved in 0.1 M borate buffer (10 mL, pH 8.5) with
0.4 M NaCl and stirred for 2 h. NaBH3CN was added to the solution
at a final concentration of 200 mM and reacted at 40 1C for 5 days.
The reaction mixture was incubated with 100 mM DTT for 12 h to














SYBR Green PCR conditions: initial denaturation step at 94 1C for 5 min; 40 cycles of denaturation at 94 1C for 30 s, annealing at 60 1C for 33 s and
extension at 72 1C for 30 s. At the end was performed a final 7 min extension at 72 1C. After amplification, melting curves were acquired and used to
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introduce a free thiol group. The mixture was dialyzed (MWCO:
2 kDa) during 4 days (2 days against 100 mM of NaCl, 25% ethanol
for 1 day and pure water for 1 day). The purified thiol end-modified
HA was freeze-dried for 2 days and characterized by 1H NMR and
Ellman’s assay. The formation of HA–Au NPs was assessed by UV-vis
spectra, TEM, elemental analysis and DLS.
Toxicity of nanomaterials in iPSC-ECs cultured in 2D
N-iPSC ECs were seeded the day before the experiment at a
density of 1  105 cells per cm2 into 96 or 384 well plates.
Nanomaterials suspended in water at 1 mg mL1 were added to
cells at a concentration between 6 and 50 mg mL1 for 24 h. In
the control, the same amount of water without NPs was added
to the cells. After 24 h incubation, cell viability was assessed by
PrestoBlues assay and apoptosis levels were monitored by
propidium iodide (PI)/Hoechst 33342 staining. PrestoBlue
assay is based on a resazurin-based solution that indicates
the reducing power of living cells and therefore measures
indirectly their number. Hoechst 33342, a blue-fluorescence
dye (excitation/emission maxima at 350/461 nm, when bound
to DNA), stains the condensed chromatin in apoptotic cells
more brightly than the chromatin in normal cells and PI is a
red-fluorescence dye (excitation/emission maxima B535/617 nm
when bound to DNA), and permeant only to dead cells. For each
measurement, the cell medium was removed, PI/Hoechst (10 mM)
was added in EGM-2 medium and incubated for 10 min, after
which the apoptosis levels were checked by microscopy by verifying
the co-localization of the PI and Hoechst signals. Cells were then
washed twice with PBS and a PrestoBlue solution (10% v/v, in
EGM-2 medium) was added for 2 h at 37 1C, upon which the
fluorescence was measured using a synergy H1 multi-mode reader
(BioTek) at 590 nm with excitation at 560 nm.
ICP-MS analyses
NP internalization was monitored by ICP-MS. In this case, the
intracellular levels of Zn (in ZnO, PEI-DS, PEI-DMNC, A1, C11
and P1C5 NPs), Ag (in Ag NPs) or Au (in LL37–Au, CM–Au and
1.4MS–Au NPs) were measured after N-iPSC EC and HGPS-iPSC
EC exposure to NPs for 24 h (with the exception of 1.4MS–Au
NPs, which were only incubated for 4 h; longer incubation
times would result in cell death) at a density of 1  105 cells per
cm2 in 96 or 384-well plates. After incubation, NPs that were not
internalized by the cells were washed (three times with PBS)
and the cells were then lysed, collected and lyophilized. The
samples were analysed by ICP-MS for the concentration of
intracellular levels of Zn, Ag or Au, depending on the NP
composition. To convert the concentration of each element
into a concentration of NP, a suspension of NPs (not exposed to
cells) was also quantified by ICP-MS. Finally, the concentration
of NP per cell was calculated.
Toxicity of nanomaterials in iPSC-ECs cultured in 3D
A 96 multiwell plate was coated with Matrigel (BD) (50 mL per
well – Matrigel was thawed at 4 1C and both tips and plates were
kept cold during the procedure) and placed at 37 1C for 30 min.
Cells were seeded on top of the polymerized Matrigel at a
density of 2  103 cells per well together with nanoparticles
(12.5 mg mL1) in EGM-2 medium (100 mL). After 24 h, bright
field images were acquired in an InCell Analyser HCA System,
and capillary-like networks analyzed using the Ibidi ACAS
image software.
Toxicity of nanomaterials in a blood vessel on a chip
The effect of NPs was evaluated under flow conditions. N-iPSC
ECs and N-iPSC SMCs were co-cultured as described in the
‘‘Culture of vascular cells in flow conditions’’ section for 5 days
in a microfluidic system. Cells were then washed and perfused
with NPs at 50 mg mL1 in EGM-2 medium at the physiological
flow rate (20 dyn cm2) for 24 h. Cell viability was assessed as
described above for static conditions.
Statistical analyses
An unpaired t test or one-way ANOVA analysis of variance with a
Bonferroni post-test was performed for statistical tests. Results
were considered statistically different when P o 0.05. Data are
shown as mean  SEM.
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